Status:
COMPLETED
IASLC Grading System as a Predictor for EGFR-TKI Therapy
Lead Sponsor:
Fudan University
Conditions:
Lung Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
The investigators previously validated the grading system proposed by International Association for the Study of Lung Cancer (IASLC) for invasive nonmucinous lung adenocarcinoma (LADC) for its reprodu...
Eligibility Criteria
Inclusion
- invasive lung adenocarcinoma patients who underwent complete resection with positive EGFR mutations in exons 18-21.
Exclusion
- adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive mucinous adenocarcinoma and other variants of adenocarcinoma
- patients with pathologic slides unavailable for re-evaluation
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
2160 Patients enrolled
Trial Details
Trial ID
NCT06131645
Start Date
January 1 2021
End Date
July 1 2023
Last Update
December 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chaoqiang Deng
Shanghai, Please Select, China, 200032